NYSE:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free CATX Stock Alerts $1.22 +0.06 (+5.17%) (As of 09:37 AM ET) Add Compare Share Share Today's Range$1.19▼$1.2950-Day Range N/A52-Week Range$0.21▼$1.91Volume263,522 shsAverage Volume4.63 million shsMarket Capitalization$759.61 millionP/E RatioN/ADividend YieldN/APrice Target$1.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Perspective Therapeutics alerts: Email Address Perspective Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside63.1% Upside$1.90 Price TargetShort InterestHealthy2.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 10 Articles This WeekInsider TradingAcquiring Shares$317,849 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.11) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.84 out of 5 starsMedical Sector386th out of 917 stocksSurgical & Medical Instruments Industry51st out of 100 stocks 4.5 Analyst's Opinion Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePerspective Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Perspective Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.91% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 30.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CATX. Previous Next 2.3 News and Social Media Coverage News SentimentPerspective Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Perspective Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows10 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $317,849.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.52% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Perspective TherapeuticsPerspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Read More CATX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CATX Stock News HeadlinesJune 5, 2024 | insidertrades.comLori A. Woods Buys 34,246 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockJune 4, 2024 | insidertrades.comInsider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CFO Purchases 25,006 Shares of StockMay 31, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III Buys 30,031 SharesMay 20, 2024 | insidertrades.comInsider Trading is Good News for These StocksMay 20, 2024 | insidertrades.comInsider Trading is Good News for These StocksJune 13 at 2:46 AM | americanbankingnews.comPerspective Therapeutics Stock to Reverse Split on Monday, June 17th (NYSE:CATX)June 12 at 7:00 AM | globenewswire.comPerspective Therapeutics Announces Inclusion in the Russell 3000® IndexJune 11 at 7:00 AM | globenewswire.comPerspective Therapeutics Announces 1-for-10 Reverse Stock SplitJune 11 at 4:00 AM | americanbankingnews.comPerspective Therapeutics, Inc. (NYSE:CATX) Receives $1.90 Average PT from BrokeragesJune 10, 2024 | globenewswire.comPerspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingJune 5, 2024 | americanbankingnews.comPerspective Therapeutics, Inc. (NYSE:CATX) Director Lori A. Woods Buys 34,246 Shares of StockJune 5, 2024 | americanbankingnews.comRobert F. Williamson III Buys 55,000 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockMay 27, 2024 | seekingalpha.comPerspective Therapeutics: An Elevated Theranostics Play Flying Under Your RadarMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Perspective Therapeutics Amid Promising Competitor Data and Treatment InnovationsMay 24, 2024 | globenewswire.comPerspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsMay 20, 2024 | globenewswire.comPerspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024May 17, 2024 | bizjournals.comGT Medical Technologies acquires cancer treatment subsidiary from Seattle companyMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)May 15, 2024 | bizjournals.comPerspective Therapeutics sells subsidiary to Arizona companyMay 15, 2024 | investorplace.comCATX Stock Earnings: Perspective Therapeutics Meets EPS for Q1 2024May 15, 2024 | washingtonpost.comPerspective Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsMay 14, 2024 | msn.comRBC Capital Initiates Coverage of Perspective Therapeutics (CATX) with Outperform RecommendationMay 9, 2024 | msn.comCantor Fitzgerald Initiates Coverage of Perspective Therapeutics (CATX) with Overweight RecommendationMay 3, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming May Investor ConferencesSee More Headlines Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:CATX CUSIPN/A CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees116Year FoundedN/APrice Target and Rating Average Stock Price Target$1.90 High Stock Price Target$3.00 Low Stock Price Target$1.40 Potential Upside/Downside+63.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,510,000.00 Net Margins-302.70% Pretax Margin-3,379.88% Return on Equity-46.38% Return on Assets-39.17% Debt Debt-to-Equity Ratio0.01 Current Ratio12.98 Quick Ratio12.98 Sales & Book Value Annual Sales$1.43 million Price / Sales507.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book4.31Miscellaneous Outstanding Shares622,630,000Free Float600,712,000Market Cap$725.36 million OptionableN/A Beta1.42 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Johan M. Spoor (Age 52)CEO & Director Comp: $855.78kMr. Jonathan R. Hunt (Age 57)CFO & Co-Principal Financial Officer Comp: $944.35kDr. Markus Puhlmann M.B.A. (Age 58)M.D., Chief Medical Officer Comp: $633.14kMr. Shane CobbExecutive Vice President of OperationsMr. Mark J. Austin CPA (Age 37)VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary Dr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExecutive Vice President of BrachytherapyMr. Amos Hedt BAPGradDip, Chief Business Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Senior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsiRhythm TechnologiesNASDAQ:IRTCInari MedicalNASDAQ:NARIICU MedicalNASDAQ:ICUIIntegra LifeSciencesNASDAQ:IARTNovoCureNASDAQ:NVCRView All CompetitorsInsiders & InstitutionsJohan M SpoorBought 100,000 shares on 6/13/2024Total: $117,000.00 ($1.17/share)Lori A WoodsBought 34,246 shares on 6/3/2024Total: $49,999.16 ($1.46/share)Robert F Williamson IIIBought 55,000 shares on 5/31/2024Total: $75,900.00 ($1.38/share)Jonathan Robert HuntBought 25,006 shares on 5/31/2024Total: $35,008.40 ($1.40/share)Robert F Williamson IIIBought 30,031 shares on 5/29/2024Total: $39,941.23 ($1.33/share)View All Insider TransactionsView All Institutional Transactions CATX Stock Analysis - Frequently Asked Questions Should I buy or sell Perspective Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Perspective Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CATX shares. View CATX analyst ratings or view top-rated stocks. What is Perspective Therapeutics' stock price target for 2024? 6 Wall Street analysts have issued twelve-month price objectives for Perspective Therapeutics' shares. Their CATX share price targets range from $1.40 to $3.00. On average, they predict the company's stock price to reach $1.90 in the next year. This suggests a possible upside of 63.1% from the stock's current price. View analysts price targets for CATX or view top-rated stocks among Wall Street analysts. How have CATX shares performed in 2024? Perspective Therapeutics' stock was trading at $1.19 at the beginning of 2024. Since then, CATX shares have decreased by 2.1% and is now trading at $1.1650. View the best growth stocks for 2024 here. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSE:CATX) announced its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $0.33 million for the quarter. Perspective Therapeutics had a negative net margin of 302.70% and a negative trailing twelve-month return on equity of 46.38%. When did Perspective Therapeutics' stock split? Perspective Therapeutics's stock reverse split on Monday, June 17th 2024. The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Perspective Therapeutics' major shareholders? Perspective Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.03%), Janus Henderson Group PLC (2.23%), Affinity Asset Advisors LLC (0.87%), Baker BROS. Advisors LP (0.03%), Virtu Financial LLC (0.02%) and RIA Advisory Group LLC (0.02%). Insiders that own company stock include Johan M Spoor, Jonathan Robert Hunt, Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann and Robert F Williamson III. View institutional ownership trends. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CATX) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.